Deerfield Management Portfolio holdings
Deerfield Management is an investment firm dedicated to healthcare, backing therapeutics, medical device, diagnostics and digital health companies at every stage, from startups to mature public businesses. Arnold Snider, a former Tiger Management managing director and Kidder Peabody pharmaceutical analyst, founded the firm in 1994 and retired in 2005. James Flynn joined in 2000 and later became chief executive. Its first healthcare innovations fund, raised in 2015, aimed at scientific advances that could lead to new treatments for genetic diseases, cancer and orphan diseases. In 2020 Deerfield took over Melinta Therapeutics, swapping secured debt for all of its equity after Melinta filed for bankruptcy. Its in-house research arm, Deerfield Discovery and Development, moves early-stage therapies from scientific discovery into the clinic.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Glaukos
GKOS
|
+$30.8M |
| 2 |
XENT
Intersect ENT
XENT
|
+$26.9M |
| 3 |
MNK
Mallinckrodt
MNK
|
+$19.7M |
| 4 |
Patterson Companies
PDCO
|
+$17.7M |
| 5 |
McKesson
MCK
|
+$13.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blueprint Medicines
BPMC
|
+$49.3M |
| 2 |
Elevance Health
ELV
|
+$43.6M |
| 3 |
PTLA
Portola Pharmaceuticals
PTLA
|
+$41.3M |
| 4 |
DBV Technologies
DBVT
|
+$36.8M |
| 5 |
Centene
CNC
|
+$36.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.83% |
| 2 | Miscellaneous | 20.43% |
| 3 | Financials | 1.75% |
Similar funds
Deerfield Management's Q2 2017 Portfolio in Review
As of Q2 2017, Deerfield Management held 112 positions worth $1.87B, down 28% from $2.59B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deerfield Management withdrew a net $899M in Q2 2017, closing 27 positions and reducing 41 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $32.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Deerfield Management opened a new position in Intersect ENT worth $33.2M.
- Deerfield Management's largest Q2 2017 buy was Intersect ENT: 1,189,577 shares worth $33.2M.
- Deerfield Management added most to Glaukos in Q2 2017, an estimated $30.8M increase.
- Deerfield Management's biggest Q2 2017 reduction was Blueprint Medicines, cutting an estimated $49.3M.
- Deerfield Management fully exited Vanda Pharmaceuticals in Q2 2017, selling an estimated $32.2M.
- Deerfield Management's ten largest holdings make up 42% of its $1.87B portfolio in Q2 2017.
- Deerfield Management opened 12 new positions and closed 27 in Q2 2017.
- Deerfield Management's portfolio value fell 28% quarter-over-quarter to $1.87B.
Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.